Norihiro Kogame1,2, MD; Rodrigo Modolo3, MD; Mariusz Tomaniak4,5, MD; Rafael Cavalcante6, MD, PhD; Fernando de Martino7, MD, PhD; Joao Tinoco8, MD; Expedito E. Ribeiro9, MD, PhD; Roxana Mehran10, MD; Carlos M. Campos9, MD, PhD; Yoshinobu Onuma4, MD, PhD; Pedro A. Lemos9, MD, PhD; Patrick W. Serruys11, MD, PhD
1. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 2. Department of Cardiology, Toho University medical center Ohashi hospital, Tokyo, Japan; 3. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, Brazil; 4. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; 5. First Department of Cardiology, Subdivision of Interventional Cardiology, Medical University of Warsaw, Warsaw, Poland; 6. Boston Scientific, Marlborough, MA, USA; 7. Department of Internal Medicine, Discipline of Cardiology, University of Triangulo Mineiro, Uberaba, MG, Brazil; 8. Unicor, Linhares, ES, Brazil; 9. Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil; 10. Icahn School of Medicine at Mount Sinai, New York, NY, USA; 11. Imperial College London, London, United Kingdom
The ASET (Acetyl Salicylic Elimination Trial) pilot study (NCT03469856) is designed to evaluate the hypothesis that a single antiplatelet therapy with prasugrel starting immediately after the procedure is feasible and safe in patients selected after successful percutaneous coronary intervention (PCI) with new-generation biodegradable polymer drug-eluting stent (DES) implantation.
The ASET pilot study is designed as a multicentre, single-arm, open-label, proof-of-concept pilot trial. Based on previous pilot studies with similar designs, a sample of 200 patients will be enrolled from 12 centres in Brazil with a stopping rule based on the occurrence of definite ...